In an unprecedented move, the Trump administration has launched a pilot program that will provide hemp-derived CBD products at no out-of-pocket cost to eligible seniors enrolled in Medicare Advantage. This marks the first time the U.S. government has subsidized cannabinoid compounds for a broad patient population.
The program, administered by CMS, stems from an executive order that reclassified marijuana to Schedule III, placing it alongside drugs like Tylenol with codeine. The FDA has also issued a memo not enforcing certain rules for qualifying oral hemp-derived CBD products.
Roughly 34 million Medicare Advantage enrollees are eligible, provided they get a physician's recommendation. The initiative could expand depending on clinical outcomes.
Wall Street reacted positively, sending public cannabis stocks higher. The Schedule III change also eases research barriers and may help cannabis companies access traditional banking, reducing their reliance on crypto-based payment systems.
However, risks remain. The pilot could be discontinued by a future administration, and the FDA's enforcement discretion is not permanent.